Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers-Reference-Cited by-同舟云学术

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers

Published:2008-12 Issue:51 Volume:26 Page:6671-6677
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Guimarães-Walker A.,Mackie N.,McCormack S.,Hanke T.,Schmidt C.,Gilmour J.,Barin B.,McMichael A.,Weber J.,Legg K.,Babiker A.,Hayes P.,Gotch F.,Smith C.,Dally L.,Dorrell L.,Cebere I.,Kay R.,Winstone N.,Moore S.,Goonetilleke N.,Fast P.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference20 articles.

1. HIV vaccines;McMichael;Annu Rev Immunol,2006

2. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya;Hanke;Nat Med,2000

3. Development of a DNA-MVA/HIVA vaccine for Kenya;Hanke;Vaccine,2002

4. Pre-clinical development of a multi-CTL epitope-based DNA prime-MVA boost vaccine for AIDS;Hanke;Immunol Lett,1999

5. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans;Mwau;J Gen Virol,2004

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunology and Nanotechnology: Effects and Affects;Nanotechnology in the Life Sciences;2021

2. Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise;Vaccines;2020-08-12

3. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge;Journal of Virology;2019-10-15

4. A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model;Vaccine;2019-08

5. Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen;Journal of Virology;2019-07-15